3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Gastrointestinal
2
Endocrine
2
Conditions
Neuroendocrine Tumors
35
Carcinoma, Neuroendocrine
10
Carcinoid Tumor
10
Neoplasms
6
Adenoma, Islet Cell
6
Carcinoma, Renal Cell
5
Carcinoma, Islet Cell
5
Somatostatinoma
4
Pheochromocytoma
4
Insulinoma
4
Glucagonoma
4
Carcinoma, Medullary
4
Paraganglioma
3
Neoplasm Metastasis
3
Gastrinoma
3
Carcinoma
3
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Neuroectodermal Tumors, Primitive
2
Liver Neoplasms
2
Head and Neck Neoplasms
2
Gastro-enteropancreatic neuroendocrine tumor
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Adenocarcinoma, Follicular
2
von Hippel-Lindau Disease
1
Zollinger-Ellison Syndrome
1
Tuberous Sclerosis
1
Interventions
lutetium Lu 177 dotatate
8
lanreotide
4
copper dotatate CU-64
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
pasireotide
3
Magnetic Resonance Spectroscopy
3
Lutetium-177
3
Lutetium
3
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
Irinotecan
2
Ga(III)-DOTATOC
2
Everolimus
2
Etoposide
2
Carboplatin
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
irinotecan sucrosofate
1
folfirinox
1
famitinib
1
cabozantinib
1
arginyllysine
1
abemaciclib
1
X-Rays
1
Sunitinib
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Everolimus
×
Endocrine
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled